allogeneic hematopoietic stem cells (Montefiore Medical Center)

This therapeutic regimen, developed by **Montefiore Medical Center**, involves the transplantation of allogeneic hematopoietic stem cells (HSCT) following a specific thiotepa-based marrow ablative conditioning (MAC) protocol. The regimen was designed for pediatric patients with high-grade, recurrent, or refractory neuroepithelial (brain) tumors and other solid tumors who lack suitable autologous stem cells. The conditioning phase utilizes a combination of thiotepa, etoposide, fludarabine, and melphalan to eradicate underlying malignant cells and suppress the host immune system. Alemtuzumab is incorporated for T-cell depletion in cases involving non-sibling donors to reduce the risk of graft-versus-host disease (GVHD). The primary therapeutic goal is to achieve hematopoietic reconstitution using healthy donor cells, which may also provide a graft-versus-tumor (GVT) effect against the solid malignancy.

Other names

Allogeneic Hematopoietic Progenitor Cell TransplantAllogeneic HSCTAllogeneic HPCT